Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)
(Incorporated in Bermuda with limited liability)
(Stock Code: 673)

EXPIRY OF LONG STOP DATE AND LAPSE OF MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF 100% EQUITY INTEREST IN THE TARGET COMPANY

Reference is made to (i) the announcement of China Health Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated 7 July 2024 in relation to the proposed acquisition of 100% equity interest in ProteinT (Tianjin) Diagnostic, Co., Ltd.*（譜天福信(天津)分子診斷技術有限公司）(the "**Acquisition**"); (ii) the announcements of the Company dated 21 August 2024 and 30 September 2024 in relation to the delay in despatch of the circular (the "**Circular**") in respect of the Acquisition; and (iii) the announcements of the Company dated 31 October 2024 and 28 February 2025 in relation to the extensions of long stop date in respect of the Acquisition and the further delays in despatch of the Circular (the "**Extension Announcements**") (collectively, the "**Announcements**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those in the Announcements.

EXPIRY OF THE LONG STOP DATE

Pursuant to the Agreement, the Completion is subject to fulfilment (or waiver) of the conditions precedent (the "**Conditions Precedent**") on or before 31 October 2024 or such other date as agreed by the parties in writing (the "**Long Stop Date**"). As disclosed in the Extension Announcements, the Long Stop Date has been extended to 30 June 2025 (the "**Extended Long Stop Date**").

As certain Conditions Precedent have not been fulfilled (or waived) by the Extended Long Stop Date and no agreement was reached by the parties to further extend the Extended Long Stop Date, the Agreement and all rights and obligations of the parties pursuant to the Agreement shall terminate.

The Board considers that the termination of the Agreement and lapse of the major transaction will not have any material adverse impact on the existing business, operation or financial position of the Group.

By order of the Board
China Health Group Limited
Chung Ho
Chief Executive Officer and Executive Director

Hong Kong, 30 June 2025

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (chairman), Mr. Chung Ho and Mr. Xing Yong; two non-executive Directors, namely, Mr. Huang Lianhai and Mr. Wang Jingming; and three independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan.